<DOC>
	<DOCNO>NCT00714558</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics fentanyl follow i.v . oral administration healthy volunteer , assess bioavailability fentanyl follow oral administration . Moreover , safety assess .</brief_summary>
	<brief_title>Pharmacokinetics Fentanyl Following Intravenous Oral Routes Administration Healthy Volunteers</brief_title>
	<detailed_description>Fentanyl , opioid ( morphine-like ) drug , demonstrate effective pain-killer medication i.v . transdermal ( skin ) rout . Fentanyl use , , surgery sedative pain-relieving action . In addition , fentanyl currently market transdermal use ( Duragesic fentanyl transdermal patch ) management chronic pain . The information bioavailability fentanyl solution , follow oral route administration , sparse . This single-center , randomize ( study drug assign chance ) , open-label , 2-treatment , 2-period , crossover study . Healthy volunteer randomly assign 1 2 treatment sequence ( AB BA ) washout period 6 14 day treatment . The washout period commence day dosing , drug administration . Prior first treatment period , healthy volunteer challenge naloxone ensure he/she dependent morphine-like drug . A negative naloxone challenge test require healthy volunteer eligible participation study . Each healthy volunteer receive 50 mg naltrexone tablet start 14 hour dose twice daily end 24 hour dose block fentanyl effect . Blood sample collect , arm opposite 1 select fentanyl i.v administration , determination blood fentanyl level schedule time point . Pulse , blood pressure , breathe rate , body temperature record monitor safety . The healthy volunteer monitor respiratory depression every 30 minute sleep period . The healthy volunteer remain clinic throughout blood sample collection period , monitor adverse event throughout study . Treatment A : 300 mcg fentanyl citrate administer i.v . 15 minute . The 300 mcg ( 6 mL ) i.v . solution dilute infused rate 1 mL/minute . Treatment B : 1 mg fentanyl citrate solution administer orally . One mg fentanyl citrate ingest 20 mL solution ; Naltrexone ( 50 mg ) administer orally healthy volunteer period start 14 hour dose , twice daily 24 hour post-dose .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Healthy , non smoker , men nonpregnant nonlactating woman Weighing minimum 60 kg within 15 % ideal weight height describe Metropolitan Life Insurance Height Weight Standards Who history show presence drug alcohol dependence abuse And , sit 5 minute , blood pressure range 100 150 mm Hg systolic 50 90 mm Hg diastolic . Any decrease systolic blood pressure stand 2 minute less equal 20 mm Hg History chronic obstructive pulmonary disease lung disease , asthma , would cause carbon dioxide retention Known allergy hypersensitivity fentanyl opioids , naltrexone naloxone Usage prescription medication ( except birth control medication , sexhormone replacement vitamin ) within 14 day Day 1 , monoamine oxide inhibitor within 21 day prior Day 1 , overthecounter medication ( except vitamin supplement acetaminophen less 2 gm/day ) herbal medication within 3 day prior Day 1 , alcohol , grapefruit juice , caffeine within 48 hour dose Consumption 450 mg caffeine per day ( eg , approximately 5 cup tea , 3 cup regular coffee , 8 can cola )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Biological Availability</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Safety</keyword>
	<keyword>Naloxone</keyword>
</DOC>